Lantheus Holdings Inc
LNTH54.900USD
-0.600-1.08%
Handelsschluss 08/29, 16:00（ET）Kurse um 15 Minuten verzögert
3.73BMarktkapitalisierung
14.68KGV TTM
mehr Informationen über Lantheus Holdings Inc Unternehmen
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.
Unternehmensinformationen
BörsenkürzelLNTH
Name des UnternehmensLantheus Holdings Inc
IPO-datumJun 25, 2015
CEOMr. Brian A. Markison
Anzahl der mitarbeiter808
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse331 Treble Cove Road
StadtNORTH BILLERICA
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl01862
Telefon19786718001
Websitehttps://www.lantheus.com/
BörsenkürzelLNTH
IPO-datumJun 25, 2015
CEOMr. Brian A. Markison
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+34.47%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+450.62%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Jamie Spaeth
Ms. Jamie Spaeth
Chief People Officer
Chief People Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Chairman of the Board
Chairman of the Board
584.72K
-4.27%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+35.31%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-31.55%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+7.64%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
25.96K
-16.67%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+10.09%
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PYLARIFY
257.65M
0.00%
DEFINITY
79.21M
0.00%
TechneLite
19.71M
0.00%
Strategic partnerships and other
10.75M
0.00%
Other precision diagnostics
5.44M
0.00%
Radiopharmaceutical oncology
0.00
0.00%
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.03%
Janus Henderson Investors
10.21%
The Vanguard Group, Inc.
10.03%
Fidelity Management & Research Company LLC
6.08%
Farallon Capital Management, L.L.C.
4.88%
Andere
57.78%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.03%
Janus Henderson Investors
10.21%
The Vanguard Group, Inc.
10.03%
Fidelity Management & Research Company LLC
6.08%
Farallon Capital Management, L.L.C.
4.88%
Andere
57.78%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
57.48%
Investment Advisor/Hedge Fund
45.03%
Hedge Fund
6.89%
Research Firm
3.61%
Individual Investor
2.32%
Pension Fund
1.94%
Bank and Trust
1.50%
Sovereign Wealth Fund
0.74%
Venture Capital
0.11%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1039
82.20M
120.88%
-4.84M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
2023Q2
790
72.85M
106.61%
-3.94M
2023Q1
733
71.94M
105.47%
-6.73M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
7.79M
11.27%
+17.69K
+0.23%
Mar 31, 2025
Janus Henderson Investors
6.26M
9.05%
-252.58K
-3.88%
May 30, 2025
The Vanguard Group, Inc.
6.99M
10.1%
-242.63K
-3.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.17M
3.14%
+148.84K
+7.36%
Mar 31, 2025
Farallon Capital Management, L.L.C.
6.02M
8.71%
+707.00K
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
2.64M
3.81%
-4.26K
-0.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.78M
2.57%
+94.57K
+5.62%
Mar 31, 2025
Wellington Management Company, LLP
909.10K
1.31%
+685.29K
+306.19%
Mar 31, 2025
Westfield Capital Management Company, L.P.
1.59M
2.3%
+34.05K
+2.19%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
1.41M
2.04%
-96.91K
-6.42%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
Invesco S&P MidCap 400 GARP ETF
2.15%
Harbor Health Care ETF
2.04%
Alpha Architect US Quantitative Value ETF
1.96%
SPDR S&P Health Care Equipment ETF
1.85%
Distillate Small/Mid Cash Flow ETF
1.13%
Invesco S&P MidCap 400 Pure Growth ETF
1.12%
Janus Henderson US Sustainable Equity ETF
1.12%
Fidelity Stocks for Inflation ETF
1.09%
Pacer US Cash Cows Growth ETF
0.75%
First Trust Small Cap US Equity Select ETF
0.68%
Mehr Anzeigen
Invesco S&P MidCap 400 GARP ETF
Anteil2.15%
Harbor Health Care ETF
Anteil2.04%
Alpha Architect US Quantitative Value ETF
Anteil1.96%
SPDR S&P Health Care Equipment ETF
Anteil1.85%
Distillate Small/Mid Cash Flow ETF
Anteil1.13%
Invesco S&P MidCap 400 Pure Growth ETF
Anteil1.12%
Janus Henderson US Sustainable Equity ETF
Anteil1.12%
Fidelity Stocks for Inflation ETF
Anteil1.09%
Pacer US Cash Cows Growth ETF
Anteil0.75%
First Trust Small Cap US Equity Select ETF
Anteil0.68%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
